 | | Vol. 14.35 – 5 September, 2023 |
| |
|
|
| Investigators showed lower levels of miR-142 in CD34+CD38− blasts from blast crisis (BC) chronic myeloid leukemia (CML) patients than in those from chronic phase CML patients, suggesting that miR-142 deficit was implicated in BC evolution.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Targeting the branched-chain amino acids transporter SLC7A5 with JPH203 inhibited oxidative phosphorylation and elicited strong anti-leukemia effects, specifically in mouse and patient AML samples while sparing healthy bone marrow cells.
[Blood Advances] |
|
|
|
| Researchers investigated the prognostic role and functional significance of cytohesin-1 (CYTH1) in AML. Analysis of AML patient data from the GEPIA and BloodSpot databases revealed that CYTH1 was significantly overexpressed in AML and independently correlated with prognosis.
[Acta Pharmacologica Sinica] |
|
|
|
| Investigators profiled monocytes and hematopoietic stem cell progenitors from chronic heavy alcohol drinking rhesus macaques using a combination of functional assays and single-cell genomics.
[Stem Cell Reports] |
|
|
|
| Scientists investigated whether azacitidine (Aza) was effective against FUS-ERG. Stable Ba/F3 transfectants with FUS-ERG were repeatedly exposed to Aza for seven days of treatment and at 21-day intervals to investigate Aza sensitivity.
[Scientific Reports] |
|
|
|
| Researchers analyzed the different phases of regeneration following transplantation. They found that regenerating HSCs initially produced rapidly expanding progenitors and displayed distinct changes in fatty acid metabolism and glycolysis.
[Experimental Hematology] |
|
|
|
| APTEN-knockdown AML animal model was generated to assess the impact of conditional phosphatases of regenerating liver 2 (PRL2) inhibition on the level of PTEN protein and the development and progression of AML.
[JCI Insight] |
| |
|
|
| Researchers compared outcomes, of 1609 patients with secondary AML undergoing HSCT in first complete remission from MUD from 2010 to 2021, receiving or not receiving anti-thymocyte globulin.
[Bone Marrow Transplantation] |
|
|
|
| | Investigators conducted a Phase I, dose-escalation study of selinexor with mitoxantrone, etoposide, and cytarabine in 23 patients aged < 60 years with relapsed or refractory AML. [Leukemia & Lymphoma] |
|
|
|
|
| The authors shed light on the relationship between zinc finger proteins (ZNF) and the regulation of the hematopoietic tissue. They include works with different designs, including both in vitro and in vivo studies, detailing how ZNF might regulate hematopoiesis.
[Journal Of Trace Elements In Medicine And Biology] |
| |
|
|
| Beam Therapeutics, Inc. announced that the first patient was treated with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy.
[Beam Therapeutics, Inc.] |
|
|
|
|
| September 28 – 30, 2023
New York, New York, United States |
|
|
|
|
|
| | Technical University of Denmark – Kongens Lyngby, Denmark |
|
|
|
| | The Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
| | Center for Biologics Evaluation and Research – Silver Spring, Maryland, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | University of Missouri – Columbia, Missouri, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
